1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Pregabalin |
| brand | String | Lyrica (IR), Lyrica CR |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Gabapentinoids|Gabapentinoid]] • [[:Category:Anticonvulsants|Anticonvulsant]] • [[:Category:Neuropathic pain medicines|Neuropathic pain medicine]] • [[:Category:Schedule V controlled substances|Schedule V controlled substance]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' |
| starting_dose | String | Neuropathic pain: 75 mg PO BID, titrate to 150 mg BID after 1 week. Fibromyalgia: 75 mg PO BID, titrate to 150 mg BID. Anxiety (off-label): 75-150 mg/day divided BID-TID |
| preparations | String | Capsules 25, 50, 75, 100, 150, 200, 225, 300 mg; oral solution 20 mg/mL; Lyrica CR tablets 82.5, 165, 330 mg |
| fda_max | String | 600 mg/day (seizures); 450 mg/day (fibromyalgia and neuropathic pain) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Neuropathic pain and fibromyalgia effect emerges over 1-2 weeks |
| duration | String | BID-TID dosing for IR; once-daily for CR |
| halflife | String | 6.3 hours'"`UNIQ--ref-00000026-QINU`"' |
| bioavailability | String | ≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)'"`UNIQ--ref-00000027-QINU`"' |
| pregnancy | String | Some signal for major congenital malformations; limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | '''[[USLegal:Schedule V|Schedule V controlled substance]] in US (federally)''', distinct from gabapentin which remains federally unscheduled'"`UNIQ--ref-00000028-QINU`"' |
